LungLife AI, Inc.

("LungLife" or the "Company")

Confirmation of AGM

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, confirms that its Annual General Meeting ("AGM") will be held at 4:00 P.M. (BST) on Wednesday 5 June 2024, at Investec Bank plc, 30 Gresham Street, London, EC2V 7QP.

For those shareholders who would like to dial into the meeting, please register by emailing LungLifeAI@walbrookpr.com or calling +44 (0)20 7933 8780 and the dial in link will be sent by email.

The results of voting on the resolutions will be announced via a regulatory information service and posted on the Company's website as soon as practicable after the AGM.

For further information please contact:

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com

Our Purpose is to be a driving force in the early detection to lung cancer.  Our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.